Annual EBIT
-$385.67 M
-$6.25 M-1.65%
December 31, 2024
Summary
- As of March 3, 2025, RLAY annual earnings before interest & taxes is -$385.67 million, with the most recent change of -$6.25 million (-1.65%) on December 31, 2024.
- During the last 3 years, RLAY annual EBIT has fallen by -$158.67 million (-69.90%).
- RLAY annual EBIT is now -673.06% below its all-time high of -$49.89 million, reached on December 31, 2018.
Performance
RLAY EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$84.98 M
+$11.39 M+11.82%
December 31, 2024
Summary
- As of March 3, 2025, RLAY quarterly earnings before interest & taxes is -$84.98 million, with the most recent change of +$11.39 million (+11.82%) on December 31, 2024.
- Over the past year, RLAY quarterly EBIT has increased by +$27.15 million (+24.21%).
- RLAY quarterly EBIT is now -342.88% below its all-time high of $34.99 million, reached on December 31, 2020.
Performance
RLAY Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$385.67 M
+$9.28 M+2.35%
December 31, 2024
Summary
- As of March 3, 2025, RLAY TTM earnings before interest & taxes is -$385.67 million, with the most recent change of +$9.28 million (+2.35%) on December 31, 2024.
- Over the past year, RLAY TTM EBIT has dropped by -$12.31 million (-3.30%).
- RLAY TTM EBIT is now -2251.38% below its all-time high of -$16.40 million, reached on March 31, 2019.
Performance
RLAY TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
RLAY EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -1.6% | +24.2% | -3.3% |
| 3 y3 years | -69.9% | -27.1% | -69.9% |
| 5 y5 years | -358.9% | -229.0% | -358.9% |
RLAY EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -69.9% | at low | -27.1% | +24.2% | -69.9% | +2.4% |
| 5 y | 5-year | -591.2% | at low | -342.9% | +24.2% | -591.2% | +2.4% |
| alltime | all time | -673.1% | at low | -342.9% | +24.2% | -2251.4% | +2.4% |
Relay Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$385.67 M(+1.6%) | -$84.98 M(-11.8%) | -$385.67 M(-2.4%) |
| Sep 2024 | - | -$96.37 M(-14.1%) | -$394.96 M(+5.8%) |
| Jun 2024 | - | -$112.13 M(+21.6%) | -$373.37 M(+1.1%) |
| Mar 2024 | - | -$92.19 M(-2.2%) | -$369.44 M(-2.6%) |
| Dec 2023 | -$379.42 M(+22.0%) | -$94.26 M(+26.1%) | -$379.42 M(+2.9%) |
| Sep 2023 | - | -$74.78 M(-30.9%) | -$368.55 M(-2.1%) |
| Jun 2023 | - | -$108.20 M(+5.9%) | -$376.41 M(+8.8%) |
| Mar 2023 | - | -$102.18 M(+22.5%) | -$345.82 M(+11.2%) |
| Dec 2022 | -$310.95 M(+37.0%) | -$83.39 M(+0.9%) | -$310.95 M(+5.6%) |
| Sep 2022 | - | -$82.63 M(+6.5%) | -$294.44 M(+8.7%) |
| Jun 2022 | - | -$77.61 M(+15.3%) | -$270.80 M(+7.5%) |
| Mar 2022 | - | -$67.32 M(+0.6%) | -$251.92 M(+11.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | -$227.01 M(+306.9%) | -$66.89 M(+13.4%) | -$227.01 M(+81.4%) |
| Sep 2021 | - | -$58.99 M(+0.5%) | -$125.13 M(+21.8%) |
| Jun 2021 | - | -$58.73 M(+38.5%) | -$102.75 M(+43.2%) |
| Mar 2021 | - | -$42.41 M(-221.2%) | -$71.74 M(+28.6%) |
| Dec 2020 | -$55.80 M(-33.6%) | $34.99 M(-195.6%) | -$55.80 M(-52.2%) |
| Sep 2020 | - | -$36.61 M(+32.1%) | -$116.62 M(+14.4%) |
| Jun 2020 | - | -$27.72 M(+4.8%) | -$101.92 M(+8.3%) |
| Mar 2020 | - | -$26.46 M(+2.4%) | -$94.10 M(+12.0%) |
| Dec 2019 | -$84.05 M(+68.5%) | -$25.83 M(+17.9%) | -$84.05 M(+44.4%) |
| Sep 2019 | - | -$21.91 M(+10.1%) | -$58.22 M(+60.3%) |
| Jun 2019 | - | -$19.91 M(+21.4%) | -$36.31 M(+121.4%) |
| Mar 2019 | - | -$16.40 M | -$16.40 M |
| Dec 2018 | -$49.89 M | - | - |
FAQ
- What is Relay Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Relay Therapeutics?
- What is Relay Therapeutics annual EBIT year-on-year change?
- What is Relay Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Relay Therapeutics?
- What is Relay Therapeutics quarterly EBIT year-on-year change?
- What is Relay Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Relay Therapeutics?
- What is Relay Therapeutics TTM EBIT year-on-year change?
What is Relay Therapeutics annual earnings before interest & taxes?
The current annual EBIT of RLAY is -$385.67 M
What is the all time high annual EBIT for Relay Therapeutics?
Relay Therapeutics all-time high annual earnings before interest & taxes is -$49.89 M
What is Relay Therapeutics annual EBIT year-on-year change?
Over the past year, RLAY annual earnings before interest & taxes has changed by -$6.25 M (-1.65%)
What is Relay Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of RLAY is -$84.98 M
What is the all time high quarterly EBIT for Relay Therapeutics?
Relay Therapeutics all-time high quarterly earnings before interest & taxes is $34.99 M
What is Relay Therapeutics quarterly EBIT year-on-year change?
Over the past year, RLAY quarterly earnings before interest & taxes has changed by +$27.15 M (+24.21%)
What is Relay Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of RLAY is -$385.67 M
What is the all time high TTM EBIT for Relay Therapeutics?
Relay Therapeutics all-time high TTM earnings before interest & taxes is -$16.40 M
What is Relay Therapeutics TTM EBIT year-on-year change?
Over the past year, RLAY TTM earnings before interest & taxes has changed by -$12.31 M (-3.30%)